BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL

October 22, 2024

News Release

BioPorto is proud to have Nine of the top-ten best US Children’s hospitals as customers of NGAL

COPENHAGEN, DENMARK and BOSTON, MA, USA, October 22, 2024, (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto or Company) (CPH:BIOPOR), an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), today reported that a group if its partnership hospitals has been ranked among the best pediatric hospitals.

In October 2024, US News & World Report released its rankings of the Best Pediatric Hospitals in the United States¹. According to the ranking, children’s hospitals awarded a “Best” designation excel at factors such as clinical outcomes, compliance with established best practices, and level and quality of hospital resources directly related to patient care.

The US News’ Top-Ten honor roll, comprising the hospitals with best rankings across specialties, were Boston Children's Hospital, Children's Hospital Colorado, Children's Hospital Los Angeles, Children's Hospital of Philadelphia, Children's National Hospital, Cincinnati Children's, Nationwide Children's Hospital, Rady Children's Hospital, Seattle Children's Hospital and Texas Children's Hospital.

Nine of the top-ten hospitals on the honor roll list have implemented or are implementing BioPorto’s neutrophil gelatinase-associated lipocalin (NGAL) tests (RUO) for clinical research including assessment of the risk of Acute Kidney Injury (AKI) in critically ill pediatric patients.

Jennifer Zonderman, SVP Global Marketing at BioPorto, comments: “We are very encouraged to see our partners on the list of the best children’s hospitals in the US. Their expertise and commitment to providing the best possible care for their patients is indeed very established and well earned. The fact that these prominent institutions choose to work with us as part of that commitment is a strong testament to our technology's capabilities and its importance in risk assessment of very ill patients.”

BioPorto's ProNephro AKI (NGAL), currently cleared by the US Food and Drug Administration (FDA) for patients 3 months through 21 years of age, has been widely recognized for its groundbreaking potential in refining AKI diagnosis.  The biomarker NGAL is a direct real-time marker of kidney cell damage and can potentially detect AKI days earlier than previously possible.